Last reviewed · How we verify
AUMOLERTINIB MESYLATE
At a glance
| Generic name | AUMOLERTINIB MESYLATE |
|---|---|
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer (PHASE2, PHASE3)
- PLATFORM Study of Precision Medicine for Rare Tumors (PHASE2)
- Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers (PHASE1)
- A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation (NA)
- A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status (PHASE1)
- Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AUMOLERTINIB MESYLATE CI brief — competitive landscape report
- AUMOLERTINIB MESYLATE updates RSS · CI watch RSS